A Study of Rapamycin Combined With Intravesical BCG in Patients With Non-muscle Invasive Bladder Cancer

Inclusion Criteria: * Pathologically (histologically) proven diagnosis of non-muscle invasive (Ta, Tis or T1) bladder cancer * In their treating physician's opinion is a good candidate for BCG therapy * Be able to give informed consent * Be age 18 or older * Not be in an immunosuppressed state (e.g. HIV, use of chronic steroids) * Not have active, uncontrolled infections * Not be on agents known to alter rapamycin metabolism significantly * Not have a reported history of liver disease (e.g. cirrhosis) * Not have a prior history of non-bladder cancer unless the cancer is clinically stable and not requiring active treatment except basal cell carcinoma or squamous cell carcinoma of the skin. * Not pregnant, or taking effective contraception before rapamycin therapy, during therapy and for 12 weeks after discontinuation of therapy. Exclusion Criteria: * Have muscle-invasive (≥T2) bladder cancer * Unable to give informed consent * Age \< 18 * Immunosuppressed state (e.g. HIV, use of chronic steroids) * Active, uncontrolled infections * On agents known to alter rapamycin metabolism significantly * Another cancer requiring active treatment (except basal cell carcinoma or squamous cell carcinoma of the skin) * Patients at risk of pregnancy who are unwilling or unable to take effective contraception before rapamycin therapy, during therapy, and for 12 weeks after discontinuation of therapy. * Individuals with a reported history of liver disease (e.g. cirrhosis) * Individuals who are not a good candidate for BCG in their treating physician's opinion